Evidence map›Paper›PMID 23770853›Full record

ArticleOncogene2014

The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis.

X Lu, S J Mazur, T Lin, E Appella, Y Xu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 159 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Self-transfecting GMO-PMO chimera targetingMolecular therapy. Nucleic acids · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

X LuDivision of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.
S J MazurLaboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
T LinCenter for Regenerative Medicine and Translational Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
E AppellaLaboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Y XuDivision of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.
National Cancer Institute · USUniversity of California, San Diego · USGuangdong Academy of Medical Sciences · CN

Funding

Tumor Suppressor Protein, p53ZIABC005599 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APPELLA, ETTORE · 2009 to 2025
$8.1M
Genetic Analysis of p53 Stability and ActivityR01CA094254 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI XU, YANG · 2003 to 2012
$2.9M
Regulation of Nanog in DNA damage response, development and tumorigenesisR01CA124834 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI XU, YANG · 2007 to 2010
$969k
NCI NIH HHS CA124834NCI NIH HHS CA94254NCI NIH HHS R01 CA094254NCI NIH HHS R01 CA124834
6 · The paper itself

Abstract

Nanog is a transcription factor required for maintaining the pluripotency of embryonic stem cells, and is not expressed in most normal adult tissues. However, recent studies have indicated that Nanog is overexpressed in many types of human cancers, including breast cancer. To elucidate the physiological roles of Nanog in tumorigenesis, we developed an inducible Nanog transgenic mouse model, in which the expression of Nanog in adult tissues can be induced via LoxP/Cre-mediated deletion. Our findings indicate that overexpression of Nanog in the mammary gland is not sufficient to induce mammary tumor. However, when coexpressed with Wnt-1 in the mouse mammary gland, it promotes mammary tumorigenesis and metastasis. In this context, Nanog promotes the migration and invasion of breast cancer cells. Microarray analysis has shown that the ectopic expression of Nanog deregulates the expression of numerous genes associated with tumorigenesis and metastasis, such as the PDGFRα gene. Our findings demonstrate the involvement of Nanog in breast cancer metastasis, and provide the basis for the reported correlation between Nanog expression and poor prognosis of human breast cancer patients. As Nanog is not expressed in most adult tissues, these findings identify Nanog as a potential therapeutic target in the treatment of Nanog-expressing metastatic breast cancer.

Indexed as

Neoplasm MetastasisAnimalsBase SequenceBreast NeoplasmsCell Line, TumorDNA PrimersFemaleGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansMammary Neoplasms, AnimalMiceMice, TransgenicNanog Homeobox ProteinReal-Time Polymerase Chain ReactionDNA PrimersHomeodomain ProteinsNanog Homeobox ProteinNanog protein, mouse

Identifiers

PMID23770853
PMCPMC3925756
OpenAlexW2084888861

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.